The treatment of metastatic ccRCC is based on targeted agents such as antiangiogenic tyrosine kinase inhibitors (VEGF receptor tyrosine kinase inhibitors, VEGFR TKI) as metastases are highly vascularized due to the overproduction of platelet-derived and vascular endothelial growth factors (PDGFs and VEGFs). Here, KDR is linked to nonpapillary renal cell carcinoma.